Literature DB >> 16077016

Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

John M Maris1, George Hii, Craig A Gelfand, Shobha Varde, Peter S White, Eric Rappaport, Saul Surrey, Paolo Fortina.   

Abstract

Many cancers are characterized by chromosomal aberrations that may be predictive of disease outcome. Human neuroblastomas are characterized by somatically acquired copy number changes, including loss of heterozygosity (LOH) at multiple chromosomal loci, and these aberrations are strongly associated with clinical phenotype including patient outcome. We developed a method to assess region-specific LOH by genotyping multiple SNPs simultaneously in DNA from tumor tissues. We identified informative SNPs at an average 293-kb density across nine regions of recurrent LOH in human neuroblastomas. We also identified SNPs in two copy number neutral regions, as well as two regions of copy number gain. SNPs were PCR-amplified in 12-plex reactions and used in solution-phase single-nucleotide extension incorporating tagged dideoxynucleotides. Each extension primer had 5' complementarity to one of 2000 oligonucleotides on a commercially available tag-array platform allowing for solid-phase sorting and identification of individual SNPs. This approach allowed for simultaneous detection of multiple regions of LOH in six human neuroblastoma-derived cell lines, and, more importantly, 14 human neuroblastoma primary tumors. Concordance with conventional genotyping was nearly absolute. Detection of LOH in this assay may not require comparison to matched normal DNAs because of the redundancy of informative SNPs in each region. The customized tag-array system for LOH detection described here is rapid, results in parallel assessment of multiple genomic alterations, and may speed identification of and/or assaying prognostically relevant DNA copy number alterations in many human cancers.

Entities:  

Mesh:

Year:  2005        PMID: 16077016      PMCID: PMC1182230          DOI: 10.1101/gr.3865305

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  38 in total

1.  Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.

Authors:  K K Matthay; C Perez; R C Seeger; G M Brodeur; H Shimada; J B Atkinson; C T Black; R Gerbing; G M Haase; D O Stram; P Swift; J N Lukens
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

2.  Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions.

Authors:  B Marshall; G Isidro; A G Martins; M G Boavida
Journal:  Cancer Genet Cytogenet       Date:  1997-07-15

3.  Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization.

Authors:  J Vandesompele; N Van Roy; M Van Gele; G Laureys; P Ambros; P Heimann; C Devalck; E Schuuring; P Brock; J Otten; J Gyselinck; A De Paepe; F Speleman
Journal:  Genes Chromosomes Cancer       Date:  1998-10       Impact factor: 5.006

4.  Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.

Authors:  L C Bowman; R P Castleberry; A Cantor; V Joshi; S L Cohn; E I Smith; A Yu; G M Brodeur; F A Hayes; A T Look
Journal:  J Natl Cancer Inst       Date:  1997-03-05       Impact factor: 13.506

5.  Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.

Authors:  N Van Roy; G Laureys; M Van Gele; G Opdenakker; R Miura; P van der Drift; A Chan; R Versteeg; F Speleman
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

6.  Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.

Authors:  N Van Roy; A Jauch; M Van Gele; G Laureys; R Versteeg; A De Paepe; T Cremer; F Speleman
Journal:  Cancer Genet Cytogenet       Date:  1997-09

7.  Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus.

Authors:  H Caron; P van Sluis; R Buschman; R Pereira do Tanque; P Maes; L Beks; J de Kraker; P A Voûte; G Vergnaud; A Westerveld; R Slater; R Versteeg
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

8.  Loss of DCC expression in neuroblastoma is associated with disease dissemination.

Authors:  M A Reale; M Reyes-Mugica; W E Pierceall; M C Rubinstein; L Hedrick; S L Cohn; A Nakagawara; G M Brodeur; E R Fearon
Journal:  Clin Cancer Res       Date:  1996-07       Impact factor: 12.531

9.  Allelic imbalance on chromosome 5q predicts long-term survival in neuroblastoma.

Authors:  S J Meltzer; S P O'Doherty; C N Frantz; K Smolinski; J Yin; A B Cantor; J Liu; M Valentine; G M Brodeur; P E Berg
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

10.  Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene.

Authors:  K Ejeskär; H Aburatani; J Abrahamsson; P Kogner; T Martinsson
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  8 in total

1.  Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors.

Authors:  Eric M Jackson; Angela J Sievert; Xiaowu Gai; Hakon Hakonarson; Alexander R Judkins; Laura Tooke; Juan Carlos Perin; Hongbo Xie; Tamim H Shaikh; Jaclyn A Biegel
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

2.  High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor.

Authors:  Eric M Jackson; Tamim H Shaikh; Sridharan Gururangan; Marilyn C Jones; David Malkin; Sarah M Nikkel; Craig W Zuppan; Luanne M Wainwright; Fan Zhang; Jaclyn A Biegel
Journal:  Hum Genet       Date:  2007-05-31       Impact factor: 4.132

3.  Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.

Authors:  Rani E George; Edward F Attiyeh; Shuli Li; Lisa A Moreau; Donna Neuberg; Cheng Li; Edward A Fox; Matthew Meyerson; Lisa Diller; Paolo Fortina; A Thomas Look; John M Maris
Journal:  PLoS One       Date:  2007-02-28       Impact factor: 3.240

4.  Genome-wide loss of heterozygosity and copy number alteration in esophageal squamous cell carcinoma using the Affymetrix GeneChip Mapping 10 K array.

Authors:  Nan Hu; Chaoyu Wang; Ying Hu; Howard H Yang; Li-Hui Kong; Ning Lu; Hua Su; Quan-Hong Wang; Alisa M Goldstein; Kenneth H Buetow; Michael R Emmert-Buck; Philip R Taylor; Maxwell P Lee
Journal:  BMC Genomics       Date:  2006-11-29       Impact factor: 3.969

5.  Identification and characterization of the lncRNA signature associated with overall survival in patients with neuroblastoma.

Authors:  Srinivasulu Yerukala Sathipati; Divya Sahu; Hsuan-Cheng Huang; Yenching Lin; Shinn-Ying Ho
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

Review 6.  Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications.

Authors:  David Seo; Geoffrey S Ginsburg; Pascal J Goldschmidt-Clermont
Journal:  J Am Coll Cardiol       Date:  2006-06-23       Impact factor: 24.094

7.  International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

Authors:  P F Ambros; I M Ambros; G M Brodeur; M Haber; J Khan; A Nakagawara; G Schleiermacher; F Speleman; R Spitz; W B London; S L Cohn; A D J Pearson; J M Maris
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640

8.  Direct inference of SNP heterozygosity rates and resolution of LOH detection.

Authors:  Xiaohong Li; Steven G Self; Patricia C Galipeau; Thomas G Paulson; Brian J Reid
Journal:  PLoS Comput Biol       Date:  2007-11       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.